BioLineRx is trading $2.51, up 6.81%, with no new company-specific announcement found to explain the October 1 pre-market rise.
- BioLineRx’s investor-relations release list shows its latest release was September 10.
- A September 30 after-hours report said shares fell 5.96% to $2.21, with no clear company-specific catalyst; the rebound follows a weak recent stretch.
- Broader markets are mixed, offering no clear same-direction driver; trading-volume details were unavailable.